Reuters (3/14, Palmer) reports executives from
agricultural, pharmaceutical and technology industries on Wednesday, called for
the US government to step up pressure on India to revise its trade and
intellectual property policies, which the industry reps claim are stifling US
exports and violating its patent rights. In testimony before the House Ways and
Means trade subcommittee, Pfizer's Chief Intellectual Property Counsel Roy
Waldron said the protectionist policy India has developed to enable its generic
drug makers to thrive is hurting US employment growth. He cited several
examples, such as India's revocation of the patent Pfizer held on the cancer
treatment Sutent (sunitinib malate), emphasizing the country's tendency to
dissolve drug patents by issuing compulsory licenses, which are supposed to be
awarded only in certain situations. Waldron concluded his testimony by urging
Federal lawmakers to address those issues actively, though direct talks with
Indian regulators and to use available policy standards to compel India to
honor intellectual property rights.
Subscribe to the DIA Daily.
View archives.
iPhone and iPad Apps available! Download "BulletinHC."DIA Daily is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare. The presence of content or advertising does not endorse, nor imply endorsement of, any products or services by the Drug Information Association. Neither BulletinHealthcare nor the Drug Information Association is liable for the use of or reliance on any information contained in this briefing.
If you would like more information about, or have a question pertaining to, DIA Membership and its benefits, please email membership@diahome.org.Click here to check your membership status.
Drug Information Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044
Copyright © 2012 by BulletinHealthcare| 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191
DIA Daily. This daily enewsletter features summaries of breaking news and information about the pharmaceutical, biotechnology, and medical device fields from thousands of global news sources. This easy-to-read enewsletter is delivered to your inbox every business morning. |
Subscribe to the DIA Daily.
View archives.
iPhone and iPad Apps available! Download "BulletinHC."DIA Daily is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare. The presence of content or advertising does not endorse, nor imply endorsement of, any products or services by the Drug Information Association. Neither BulletinHealthcare nor the Drug Information Association is liable for the use of or reliance on any information contained in this briefing.
If you would like more information about, or have a question pertaining to, DIA Membership and its benefits, please email membership@diahome.org.Click here to check your membership status.
Drug Information Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044
Copyright © 2012 by BulletinHealthcare| 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191
No comments:
Post a Comment